The Covid-19 pandemic and impact on breast cancer diagnoses: what happened in England in the first half of 2020
Breast cancer is the most commonly diagnosed cancer in women in England. Data from the NHS Cancer Waiting Time team was used to examine the impact of the COVID-19 pandemic on breast cancer diagnoses in the first half of 2020. I will briefly explain the main findings and plans for further work.
Obesity and cancer- moving beyond the epidemiology to focus on intervention research Annie S. Anderson, University of Dundee
Obesity and cancer can be an emotive topic laden with guilt and a feeling of being overburdened. It has been described as the “elephant in the room” but the bottom line is that it is time to move beyond epidemiology and mechanisms to open the door on interventional research.
Pathological features of 11337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events – results from the UK Sloane project
A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent anti-tumor response
The type 1 NKT cell stimulating glycolipid α-galactosylceramide (α-GalCer) was first identified by the Pharmaceutical Research Laboratory of Kirin Brewery in a screen for novel anti-tumor agents. Based on promising preclinical data it was tested as an anticancer drug in multiple clinical studies.
Better understanding of AML biology and survival tactics has facilitated a wave of newly approved drugs against AML and also revealed a range of targets to be exploited for treatment. In our review, we discuss what these new targets are and how targeting them in combination might be beneficial.
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomized clinical trial